Navigation Links
NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007
Date:10/25/2007

BEDMINSTER, N.J., Oct. 25 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will report its third quarter financial results and Nycomed's decision whether to proceed with ex-U.S. development and commercialization of GATTEX(TM) (teduglutide) on Thursday, November 1, 2007. NPS expects to receive notification from Nycomed at the end of this month regarding Nycomed's plans to partner with NPS on the development of GATTEX(TM) (teduglutide) outside North America. The announcement will be followed by a conference call and webcast at 5:00 p.m. EDT, featuring Dr. Anthony Coles, president and CEO, and other members of the NPS executive team.

To participate in the conference call, dial (866) 770-7051 and use passcode 53288322. International callers may dial (617) 213-8064, using the same passcode. In addition, live audio of the conference call will be simultaneously broadcast over the Internet and may be accessed on the company's web site (http://www.npsp.com).

If you are unable to participate in the live call, a replay will be available at (888) 286-8010, with passcode 16038876, until midnight EST, November 15, 2007. International callers may access the replay by dialing (617) 801-6888, using the same passcode. The webcast will also be available on the NPS website for the same period of time.

About NPS Pharmaceuticals

NPS Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. The company has drug candidates in various stages of clinical development. Additional information is available on the company's website, http://www.npsp.com.


'/>"/>
SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
4. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
5. Signal Transduction Reporting Systems Using Cis-Acting Enhancer Elements
6. Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion Transactivators
7. Versatile Reporter Vectors for Monitoring Viral Transduction
8. In Vivo Signal Transduction Pathway Reporting Systems
9. Improved Vectors for PathDetect Trans-Reporting Systems
10. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
11. Cis-Reporting System Monitors Intracellular Calcium Mobilization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... -- The report "Cryocooler Market by Type ... Support, Product Repairs & Refurbishment, Preventive Maintenance, and Customer ... published by MarketsandMarkets, the global market is expected to ... CAGR of 7.29% between 2016 and 2022. ... spread through 159 Pages and in-depth TOC on  "Cryocooler ...
(Date:4/28/2016)... ... April 28, 2016 , ... Connecticut Innovations (CI), ... today announced the launch of VentureClash , a $5 million global investment ... “VentureClash looks to attract the best early-stage companies here in Connecticut, around the ...
(Date:4/28/2016)... ... 28, 2016 , ... As part of an ongoing global ... expanding its LATAM network and logistics capabilities. Enhancements have been made to ... trial projects. , The expansion will provide unmatched clinical trial logistics services for ...
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... Cambridge ... by semantic web technology, today announced that it has been named to The Silicon ... sciences, financial services and other markets, Cambridge Semantics serves the needs of end users ...
Breaking Biology Technology:
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
(Date:3/15/2016)... JERUSALEM , March 15, 2016 ... Jerusalem , the technology-transfer company of the Hebrew University, ... developer of remote sensing technology of various human biological ... funding, raising $2.0 million from private investors. ... technology, based on the detection of electromagnetic emissions from ...
(Date:3/10/2016)... PUNE, India , March 10, 2016 ... to a new market research report "Identity and Access ... SSO, & Audit, Compliance, and Governance), by Organization Size, ... Forecast to 2020", published by MarketsandMarkets, The market is ... to USD 12.78 Billion by 2020, at a Compound ...
Breaking Biology News(10 mins):